SEC Form 4 · accession 0002031695-26-000011
Xeris Biopharma Holdings, Inc. · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin McCulloch
Officer — See Remarks
Period of report
Sep 1, 2026
Accepted (ET)
Sep 1, 2026 · 6:21 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001867096
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 1, 2026 | S | 15,000 | $8.4872 | D | 1,639,208 | D | |
| Common StockF3 | holding | — | — | — | 25,000 | I | By Spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Remarks
President and Chief Operating Officer